Adventures in babykilling
The Left unveils their latest birth control patch.
When posed with the age-old question, Would liberals prefer women fornicate with impunity, or exercise their Constitutional right to murder their unborn children?, I answered with the certainty of a housewife in one of those old Stovetop Stuffing commercials: "Abortion. The Left definitely wants every woman in America to have a late-term partial birth abortion." Shockingly, I was just as wrong. In the old less filling/tastes great debate reproductive rights advocates have been having amongst themselves for years, the consensus, at least momentarily, falls on the side of less uterine filling:
The government is considering setting higher standards for birth control drugs used by millions, saying that newer pills appear to be less effective at preventing pregnancy than those approved decades ago.Where is the Outrage? Either way, Our Nation's chastity loses. But what's even more infuriating is that regulatory overreach this egregious is allowed to happen in a so-called "free country" at all. As any Freedom-lover can tell you, the FDA has no business impeding the flow of presumably safe drugs into the marketplace -- those resources would be better spent browbeating these little floozies into getting married. Praise Him!
The Food and Drug Administration will ask a panel of experts Tuesday and Wednesday whether it should require new contraceptive drugs to meet a standard of effectiveness before they are approved for the market. ...
Government scientists are in disagreement over whether there should be a strict limit on the failure rate a drug can have and still be approved. And they are looking at requiring manufacturers to include a more representative mix of women in the clinical trials for their new products.
Companies often exclude women who smoke, are overweight or have a history of heart problems from their trials. The FDA says this makes it difficult for scientists to judge the safety and efficacy of the drugs in the real world.
Heather Boonstra, a policy analyst for Guttmacher Institute, said the FDA is likely holding its meeting now to stay abreast of a number of innovative contraceptive products that are now in development.
One such product is Wyeth Pharmaceuticals' Lybrel [Why not just call it Liberal and be done with this charade - SNBE], which is designed to be the first birth control pill for continuous use, 365 days a year. The drug is pending approval in the U.S. and in Europe. A Wyeth representative said the company would attend the meeting but did not plan to make a presentation.
Other recent innovative products have proved problematic for the agency. In September, for example, the FDA warned women that Johnson & Johnson's birth control patch Ortho Evra could raise their chances of developing blood clots in the legs and lungs. Johnson & Johnson markets a number of traditional contraceptives, including its top-selling birth control pill, Ortho Tri-Cyclen.